Abstract 6058
Background
Cancer-related fatigue (CRF) is one of the most common side effects and leads to a significant impairment of quality of life (QoL). At the same time many cancer patients suffer from malnutrition. Studies show that both physical activity and a good nutritional status reduce CRF. Until now this has only been considered in isolation. This study aims a comprehensive view to evaluate the relation of fatigue with malnutrition and level of activity.
Methods
18 patients of the oncological sports and exercise therapy at the University Hospital Halle (Saale) were examined in a cross-sectional design. Outcome measures were the relevant values of body composition, such as body mass [% of fat-free mass] (BCM [% of FFM]), extracellular mass to body cell mass (ECM / BCM) and phase angle ϕ, which were determined by bioelectrical impedance analysis (BIA). Moreover CRF with EORTC QLQ FA12, Nutritional related QoL with FAACT, History and Current Level of Activity (Questionnaire from Woll) and Malnutrition with Subjective Global Assessment (SGA). The statistical analysis was made with description and Pearson’s correlations. Following, a linear regression analysis was supplemented with an ANOVA.
Results
The correlation between physical fatigue and habitual physical activity had a correlation coefficient of -0.641 (p = 0.004). Between the physical fatigue and FAACT Total Score a negative linear correlation (correlation coefficient = -0.739, p < 0.01) could be found. The correlation of the physical fatigue and the values from the BIA did not show any significant results. The linear regression analysis showed that 47.8 % of the total fatigue could be explained by the Functional Assessment of Anorexia/Cachexia Therapy (corr. R2 = 0.478, p = 0.001) and that ECM/BCM and BCM [% of FFM] do not provide additional explanatory power.
Conclusions
It could be confirmed that the QoL of cancer patients is strongly limited by the CRF. The negative correlation between habitual activity and physical fatigue supports the hypothesis of the so-called "prehabilitation". It has been shown that it is a legitimate strategy to present nutritional status and level of physical activity in cancer patients with CRF at the same time.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
P. Jahn: Research grant / Funding (institution): Chugai. C. Leithold: Honoraria (self): Fresenius. All other authors have declared no conflicts of interest.
Resources from the same session
4290 - Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models.
Presenter: Alessio Fiascarelli
Session: Poster Display session 3
Resources:
Abstract
2167 - Neat-1: culprit lnRNA tying PIG-C, MSLN, CD80 in TNBC
Presenter: Nada Hussein
Session: Poster Display session 3
Resources:
Abstract
1829 - A novel RAF/MEK inhibitor CH5126766 in phase 1 clinical trial has an effectiveness in the combination with eribulin for the treatment of triple negative breast cancer
Presenter: Hisako Ono
Session: Poster Display session 3
Resources:
Abstract
4357 - Identification of a stemness-related gene panel associated with BET inhibition in triple negative breast cancer
Presenter: Eva Galan-Moya
Session: Poster Display session 3
Resources:
Abstract
5163 - Preclinical Evaluation targeting both IGF1R and IR in Triple Negative Breast Cancer
Presenter: Alex Eustace
Session: Poster Display session 3
Resources:
Abstract
832 - Monospecific antibody targeting of CDH11 inhibits epithelial-to-mesenchymal transition and represses cancer stem cell-like phenotype by up-regulating miR-335 in metastatic breast cancer, in vitro and in vivo.
Presenter: Jia-Hong Chen
Session: Poster Display session 3
Resources:
Abstract
3781 - Pharmacological screening with Chk1 inhibitors identify synergistic agents to overcome resistance to platinums in basal breast and ovarian cancer
Presenter: Ana Lucia Sanabria
Session: Poster Display session 3
Resources:
Abstract
3275 - Comparison of 11 circulating miRNAs and CA125 kinetics in ovarian cancer during first line treatment: data from the randomized CHIVA trial (a GINECO-GCIG study)
Presenter: Patrick Robelin
Session: Poster Display session 3
Resources:
Abstract
3391 - Inhibiting Ehmt2 and Ezh2 histone methyltransferases alters the immune microenvironment in a Trp53-/- murine ovarian cancer model
Presenter: Pavlina Spiliopoulou
Session: Poster Display session 3
Resources:
Abstract
3839 - Fenofibrate impairs pro-tumorigenic potential of cancer stem cell-like cells within drug-resistant prostate cancer cell populations.
Presenter: Tomasz Wróbel
Session: Poster Display session 3
Resources:
Abstract